Showing 3821-3830 of 9301 results for "".
- Aditxt Forms Adimune, Inc.; Appoints Dr. Friedrich Kapp as Chairman and CEOhttps://practicaldermatology.com/news/aditxt-forms-adimune-inc-appoints-dr-friedrich-kapp-as-chairman-and-ceo/2461479/Aditxt, Inc. has formed Adimune, Inc., a U.S.-based subsidiary, and plans to submit a Clinical Trial Application (CTA) for ADI-100, which consists of two DNA molecules that restore immune tolerance in autoimmune disease. The CTA application will request approval for Adimune to conduct the first-i…
- AMA Responds to Medicare Cutshttps://practicaldermatology.com/news/ama-responds-to-medicare-cuts/2461472/In response to Congress failing to prevent Medicare cuts for 2023, Jack Resneck, Jr., MD, President of the American Medical Assocation, released the following statement: The AMA is extremely disappointed and dismayed that Congress failed to prevent Medicare cuts next year, threatening the finan…
- Hydrafacial, DOCTOR BABOR Collab for New Collagen HA Boosterhttps://practicaldermatology.com/news/hydrafacial-doctor-babor-collab-for-new-collagen-ha-booster/2461461/The Beauty Health Company’s Hydrafacial launched a new booster co-created with BABOR Skincare. The new DOCTOR BABOR Collagen HA booster is inspired by DOCTOR BABOR’s formulations and developed with the BABOR Laboratories in Germany. “Hydrafacial has created the ultimate customized and personaliz…
- Garnier Debuts Product Impact Ranking Across Hair Care Rangehttps://practicaldermatology.com/news/garnier-debuts-product-impact-ranking-across-hair-care-range/2461455/Garnier is launching a digital labeling system that ranks its hair care products versus other L'Oreal Group Products based on 14 environmental factors. Product Impact Labelling ranks each product from A to E, with "A" indicating the 10% of L'Oreal Group Products in the same category with the lowes…
- Celebrities Come Together for EB Research Partnershiphttps://practicaldermatology.com/news/celebrities-come-together-for-eb-research-partnership/2461453/EB Research Partnership (EBRP) presented the third annual Venture Into Cures, an inspiring virtual event featuring moving stories about individuals and families living with Epidermolysis Bullosa (EB). Co-founders Eddie and Jill Vedder, along with their daughters Olivia and Harper Vedder, were joine…
- WHO Recommends New Name for Monkeypoxhttps://practicaldermatology.com/news/who-recommends-new-name-for-monkeypox/2461448/The World Health Organization (WHO) will begin using “mpox” as a synonym for monkeypox. Both names will be used simultaneously for one year while “monkeypox” is phased out. When the outbreak of monkeypox expanded earlier this year, racist and stigmatizing language online, in other settings and i…
- Meta-analysis: Early Use of Emollients Can Help Preventing AD in High-risk Infantshttps://practicaldermatology.com/news/meta-analysis-early-use-of-emollients-can-help-preventing-ad-in-high-risk-infants/2461445/Early application of emollients is an effective strategy for preventing atopic dermatitis (AD) in high-risk infants, according to a meta-analysis in the Journal of the European Academy of Dermatology & Venereology. The analysis included 11 randomized controlled trials involving 3,483 infants. Thr…
- Dermavant Launches First Commercial for VTAMAhttps://practicaldermatology.com/news/dermavant-launches-first-commercial-for-vtama/2461441/Dermavant Sciences launched its first commercial as part of a national, multimedia, direct-to-consumer advertising campaign for VTAMA (tapinarof) cream, 1%. Inspired by the stories of real patients, the “Topical Uprising” campaign focuses on the patient journey — tapping into the frustrations of l…
- AD News: Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapyhttps://practicaldermatology.com/news/ad-news-alphyn-biologics-completes-first-cohort-of-phase2a-clinical-trial-of-topical-therapy-1/2461432/Alphyn Biologics completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mild-to-moderate atopic dermatitis (AD) in adults and children as young as two years old. The first cohort enrolled AD patients without bacterial infection, which is sometimes…
- NEA's Eczemawise Wins Two Top Prizes from eHealthcare Leadership Awardshttps://practicaldermatology.com/news/neas-eczemawise-wins-two-top-prizes-from-ehealthcare-leadership-awards/2461424/The National Eczema Association (NEA) was presented with two top prizes from the eHealthcare Leadership Awards for its app, EczemaWise. EczemaWise received the highest-level Platinum prize in the categories of both Best Care/Disease Management and Best Mobile App. The award recipients in all catego…